Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Go online to PeerView.com/KPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid progress in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has practice-changing implications for pathologists, oncologists, and the broader multidisciplinary lung cancer care team. In addition to multiple targeted therapy options available for patients with metastatic NSCLC with more commonly occurring EGFR mutations, new agents have recently been approved by the FDA for those with less common but highly important EGFR exon 20 insertion mutations. Furthermore, EGFR-targeted therapy is now also transitioning from the advanced to early-stage settings of lung cancer, with the first regulatory approval granted for adjuvant therapy so far, and further developments are anticipated. The expansion of the treatment arsenal means that appropriate biomarker testing is increasingly more important, including the selection and use of correct testing methodologies to identify all patients with diverse EGFR mutations who can benefit from novel targeted therapies. Are you prepared for the enhanced precision and granularity in testing and treatment that is now required? This PeerView activity highlights all the recent need-to-know advances in EGFR-targeted therapy, along with the implications for pathology and oncology practice. Top experts will also provide useful, case-based guidance on what, how, and when to test, and how to accurately interpret the complex results of EGFR mutation testing to guide individualized treatment decisions for patients with EGFR-mutated NSCLC. Upon completion of this CE activity, participants will be able to: Describe the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, including in earlier disease stages, Apply the latest recommendations and best practices for biomarker testing to detect common and less common EGFR mutations in NSCLC, Implement multidisciplinary strategies for biomarker testing and individualized treatment selection throughout the NSCLC disease continuum, Integrate established, new, and investigational targeted therapies into the treatment of patients with EGFR-mutated NSCLC according to the latest evidence and guidelines and patient needs, values, and preferences.